IDEAYA Biosciences IDYA
- Market cap
- $3.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 13.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $234.1M
- Net margin
- −74.8%
- Free cash flow yield
- −3.7%
IDEAYA Biosciences trades at 13.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $234.1M over the last twelve months with a −75% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8M−73% | $3.9M−3% | $0 | $0 | $0 | $7M+79% | n/a | n/a | $207.8M | $10.9M+55% | $6.6M | $8.9M | |
| R&D | $33.7M+51% | $38.8M+57% | $42.8M+54% | $54.5M+87% | $57.2M+70% | $140.2M+262% | $70.9M+66% | $74.2M+36% | $83M+45% | $86.6M−38% | $95.7M+35% | $108.7M+46% |
| SG&A | $7.9M+18% | $7.1M+23% | $8.2M+30% | $10.4M+47% | $9.7M+24% | $11M+55% | $13.5M+64% | $14.6M+40% | $16.4M+68% | $18.8M+72% | $19.4M+44% | $22.5M+54% |
| −$33.5M | −$41.9M+59% | −$51M+94% | −$64.9M+99% | −$66.9M+100% | −$144.1M+244% | −$84.4M+65% | −$88.8M+37% | $108.5M | −$94.6M−34% | −$108.5M+29% | −$122.3M+38% | |
| Net income | −$27.4M | −$34M+40% | −$39.6M+67% | −$52.8M+89% | −$51.8M+89% | −$130.3M+284% | −$72.2M+82% | −$77.5M+47% | $119.2M | −$83.3M−36% | −$98.5M+37% | −$112.5M+45% |
| −$0.46 | −$0.52+4% | −$0.53+8% | −$0.68+36% | −$0.60+30% | −$1.49+187% | −$0.82+55% | −$0.88+29% | $1.33 | −$0.94−37% | −$1.11+35% | −$1.22+39% | |
| 60M+46% | 65.2M+36% | 75.1M+55% | 78M+39% | 86.2M+44% | 87.3M+34% | 88.4M+18% | 88.5M+14% | 89.7M+4% | 88.6M+1% | 88.7M+0% | 92.1M+4% |
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest IDEAYA Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IDYAIDEAYA Biosciences | $3.1B | n/m | n/a | 13.0× | n/m | −74.8% | |
| NRIXNurix Therapeutics | $2.8B | 11.1× | 11.0× | 4.0× | n/m | 42.0% | |
| OGNOrganon | $3.6B | 18.2× | 6.0× | 0.6× | −3% | 3.5% | |
| LQDALiquidia | $3.7B | 30.1× | 49.4× | 8.3× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 117× | 8.5× | +76% | 6.1% | |
| PBHPrestige Consumer Healthcare | $2.4B | 13.9× | 15.3× | 2.1× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| INDVIndivior Pharmaceuticals | $4.3B | 10.2× | 19.9× | 3.1× | +16% | 32.8% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.7× | 37.6× | 21.1× | +55% | 67.9% | |
| Peer median | $3.2B | 15.5× | 20.7× | 2.7× | +21% | 17.2% |
More on IDEAYA Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .